Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft tissue sarcomas Journal Article

  

Authors:	Sordillo, P. P.; Magill, G. B.; Welt, S.
Article Title:	Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft tissue sarcomas
Abstract:	A phase II study of methylglyoxal-bis-guanylhydrazone (methyl-GAG) was conducted on 20 previously treated patients with soft-tissue sarcomas. no major responses were seen among 18 adequately treated patients. Toxicity including severe fatigue, muscle pains, and pharyngitis was noted in most patients. Methyl-GAG does not have significant antitumor activity in previously treated patients with soft-tissue sarcomas.
Keywords:	cancer chemotherapy; clinical article; fatigue; diarrhea; drug efficacy; phase 2 clinical trial; nausea; vomiting; myalgia; soft tissue; gastrointestinal toxicity; soft tissue sarcoma; drug toxicity; drug therapy; adverse drug reaction; therapy; intravenous drug administration; mitoguazone; pharynx; pharyngitis; intoxication; human; priority journal
Journal Title:	American Journal of Clinical Oncology
Volume:	8
Issue:	4
ISSN:	0277-3732
Publisher:	Lippincott Williams & Wilkins
Date Published:	1985-08-01
Start Page:	316
End Page:	318
Language:	English
DOI:	10.1097/00000421-198508000-00008
PUBMED:	3909804
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022359507&doi=10.1097%2f00000421-198508000-00008&partnerID=40&md5=92f03eea70cef47a75d72bb1aabe25e0
Notes:	Article -- Export Date: 26 October 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/189514